文献速递头颈外科

头颈癌放疗中断与结局:三项随机临床试验的二次分析

Treatment Interruption and Outcomes in Head and Neck Cancer: A Secondary Analysis of 3 Randomized Clinical Trials.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2026-01-01

该研究对NRG/RTOG 0129、0522和1016三项随机临床试验进行回顾性二次分析,纳入1549例接受放疗的头颈鳞癌患者,评估放疗中断与局部区域失败(LRF)和总生存(OS)的关联。结果显示,每7天放疗中断与LRF风险(HR 1.45,95%CI 1.12-1.89)和OS风险(HR 1.41,95%CI 1.07-1.86)升高相关,且p16阳性口咽癌与局部晚期头颈鳞癌的3年LRF下降幅度不同。

要点

  • 每7天放疗中断与LRF风险升高45%、死亡风险升高41%相关。
  • p16阳性口咽癌7天中断预测3年LRF下降4.1%,局部晚期头颈鳞癌下降9.1%。
  • 局部晚期或高分期患者受放疗中断影响可能最大。

核心结论

  • 放疗中断可能与头颈鳞癌的局部区域失败和总生存负相关,关联幅度随p16状态和临床特征变化。
  • 应全局性避免治疗中断,局部晚期头颈鳞癌或更高分期患者可能受影响最大。

研究设计与样本

  • 对3项随机临床试验(NRG/RTOG 0129、0522、1016)进行回顾性二次分析,纳入接受放疗的头颈鳞癌患者。
  • 二分类模型纳入1549例患者(200例女性[12.9%];平均[SD]年龄57[6]岁;1048例p16阳性口咽癌[67.7%],501例局部晚期头颈鳞癌[32.3%]),其中439例(28.3%)出现放疗中断。
  • 连续模型纳入1083例(69.9%)有放疗中断时长数据的患者。

主要发现

  • 二分类放疗中断与LRF的HR为1.04(95%CI 0.90-1.36),与OS的HR为1.22(95%CI 0.99-1.50)。
  • 作为连续预测因子,每7天中断对应LRF的HR为1.45(95%CI 1.12-1.89),OS的HR为1.41(95%CI 1.07-1.86)。
  • 分析未提示p16状态存在效应修饰,结果来自估计两组共同放疗中断效应的模型。
  • 基于包含临床和肿瘤特征模型的协变量调整预测,平均7天放疗中断与3年LRF下降相关:p16阳性口咽癌下降4.1%,局部晚期头颈鳞癌下降9.1%。
  • 放疗中断导致的预测3年LRF detriment范围从非T4、非N3的p16阳性口咽癌患者的2.0%到T4N3 p16阴性局部晚期头颈鳞癌患者的11.2%。

临床怎么用

  • 临床应尽量避免头颈鳞癌放疗中断,尤其对局部晚期或高分期患者。
  • 对p16阳性口咽癌和局部晚期头颈鳞癌可依据中断时长评估LRF风险增加程度。

局限性

  • 为回顾性二次分析,可能存在未测量混杂。
  • 连续模型仅纳入69.9%有中断时长数据的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Historical evidence demonstrated that delays or interruptions in radiotherapy (RT) are associated with poorer oncologic outcomes in head and neck squamous cell carcinoma (HNSCC). Substantial concerns arose during the COVID-19 pandemic, when treatment schedules were frequently disrupted. OBJECTIVE: To determine the association of RT interruptions with locoregional failure (LRF) and overall survival (OS). DESIGN, SETTING, AND PARTICIPANTS: This retrospective review and secondary analysis of 3 randomized clinical trials (NRG/RTOG 0129, 0522, and 1016) included patients enrolled in the trials who were treated with RT. Patients with HNSCC were grouped as (1) p16-positive oropharynx (p16+ OPSCC) and (2) p16-negative oropharynx and all other subsites regardless of p16 status (called locally advanced HNSCC [LAHNSCC])). Cox proportional hazards models were fit to assess the association of an RT interruption (binary model) and length of RT interruption (continuous model) with LRF and OS. EXPOSURES: Presence of RT interruption. MAIN OUTCOMES AND MEASURES: LRF and OS. RESULTS: There were 1549 patients (200 female patients [12.9%]; mean [SD] age, 57 [6] years; 1048 p16+ OPSCC [67.7%]; 501 LAHNSCC [32.3%]) who were included in the binary model; 439 (28.3%) had RT interruption. There were 1083 patients (69.9%) with available length of RT interruption (continuous model). A binary RT interruption was associated with hazard ratios (HRs) of 1.04 (95% CI, 0.90-1.36) for LRF and 1.22 (95% CI, 0.99-1.50) for OS. As a continuous predictor, each 7-day interruption corresponded to HRs of 1.45 (95% CI, 1.12-1.89) for LRF and 1.41 (95% CI, 1.07-1.86) for OS. Analyses did not indicate effect modification by p16 status, and results are presented from models that estimated the effect of RT interruption across both groups. Using covariate-adjusted predictions from models that included clinical and tumor characteristics, a mean 7-day interruption in RT was associated with a 3-year LRF decrement of 4.1% in p16+ OPSCC and 9.1% in LAHNSCC. Predicted 3-year LRF detriment due to RT interruption ranged from 2.0% for a patient with non-T4, non-N3, p16+ OPSCC to 11.2% for a patients with LAHNSCC with a T4N3 p16-negative cancer. CONCLUSIONS AND RELEVANCE: The secondary analysis suggests that RT treatment interruptions may be negatively associated with LRF and OS in HNSCC, but the magnitude of the association varies depending on p16 status and clinical characteristics. While treatment interruptions should globally be discouraged, patients with LAHNSCC or higher-stage disease may be most affected. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT00047008; NCT00265941; NCT01302834.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Gharzai LA, Morris E, Schipper MJ, et al. Treatment Interruption and Outcomes in Head and Neck Cancer: A Secondary Analysis of 3 Randomized Clinical Trials. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 41343184. doi:10.1001/jamaoto.2025.4203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。